Top Markets
#1 EXOD EXOD +22.08%
#2 Ontology Gas Ontology Gas +19.28%
#3 Wrapped STX (Velar) Wrapped STX (Velar) +17.82%
#4 Geodnet Geodnet +17.14%
#5 Derive Derive +16.24%
#6 Neiro Neiro +14.58%
#7 Status Status +13.62%
#8 Pons Pons +12.49%
#9 Ergo Ergo +11.89%
#10 Collect on Fanable Collect on Fanable +10.15%
Coin of the day
EXOD EXOD
Settings
Language
ENGLISH
Currency
USD
Theme
Apollomics, Inc. Apollomics, Inc.

Apollomics, Inc.

APLM
Rank in Stocks #25246
Apollomics, Inc., a biotechnology enterprise established in 2015 and... Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
Share Price
$23.57
Last synced: 2026-08-20
Market Cap
$51.76M
Change (1 day)
-0.08%
Change (1 year)
289.59%
Country
US
Trade Apollomics, Inc. (APLM)

Category

Healthcare
P/B ratio for Apollomics, Inc. (APLM)
P/B ratio as of 2026 TTM: 0
According to Apollomics, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Apollomics, Inc. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US